>H)&<APH%+2VY<-%+{L,,BST>9KM#D
SYSTEM PROCESSING...
>H)&<APH%+2VY<-%+{L,,BST>9KM#D
SYSTEM PROCESSING...
Posted: 2025-04-20 17:18:56 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-04-20 17:19:23 UTC
Verified By
Rollup News
A new study reveals that senolytic molecules, such as dasatinib and quercetin, can slow age-related hearing loss in mice by protecting cochlear cells and reducing inflammation. Quercetin's activation of SIRT1, a longevity enzyme, may also contribute to these results. Clinical trials with D+Q are ongoing at the Mayo Clinic, typically using 100mg dasatinib and 1000mg quercetin in consecutive 3-day cycles monthly or weekly. The study demonstrated that this senolytic combination preserved hearing by targeting senescent cells in the cochlea, which release inflammatory molecules.
Senolytic molecules (dasatinib + quercetin) slow age-related hearing loss in mice.
Protection of cochlear cells and reduction of inflammation.
Quercetin activates SIRT1, a longevity enzyme.
Clinical trials with D+Q are in progress at the Mayo Clinic.
Senolytics target senescent cells in the cochlea.
Age-related hearing loss.
Inflammation in the cochlea.
Senescent cells affecting tissue function.